Recent Posts
Deals•Feb 19, 2026
Altesa Raises $75M for Oral Respiratory Med
Altesa announced a $75 million fundraising round to develop its oral respiratory medication. The capital will support further clinical development and commercialization efforts.
Endpoints News
Deals•Feb 18, 2026
Faeth Goes Public via Merger with Sensei, Raising $200M
Faeth announced its public listing through a merger with Sensei, generating $200 million from a stock sale. The transaction marks Faeth's entry into the public markets.
Endpoints News
Deals•Feb 17, 2026
Six Biotech Companies File for HKEX IPOs
Six biotechnology firms have filed for initial public offerings on the Hong Kong Stock Exchange, signaling a push into Asian capital markets. The filings were announced on February 17, 2026.
Endpoints News
Deals•Feb 13, 2026
Gilead Acquires Global Rights to Genhouse Bio's Oral Cancer Drug for $80M
Gilead announced it will acquire the global rights to an oral cancer drug from China-based biotech Genhouse Bio, paying $80 million upfront. The deal expands Gilead's oncology pipeline as Genhouse prepares for a Hong Kong IPO.
Endpoints News
Deals•Feb 10, 2026
ILiAD Biotechnologies Secures $115M Series B to Advance Whooping Cough Vaccine
ILiAD Biotechnologies announced an oversubscribed $115 million Series B financing on Tuesday. The new capital will fund pivotal Phase 3 trials for its whooping cough vaccine, accelerating development and potential market entry.
Endpoints News
Deals•Feb 10, 2026
Cascade Pharmaceuticals Raises $72M to Develop MASH, Obesity and Diabetes Drugs
Shanghai-based biotech Cascade Pharmaceuticals announced it has secured $72 million (about 500 million yuan) in new funding to advance its pipeline targeting metabolic-associated steatohepatitis (MASH), obesity, and diabetes. The capital will support preclinical and clinical development of its drug candidates.
Endpoints News
Deals•Feb 9, 2026
QuantX Biosciences Secures $85M Series B Funding Led by Lilly and Sanofi Ventures
China‑American biotech QuantX Biosciences announced a $85 million Series B round, led by the venture arms of Eli Lilly and Sanofi. The funding will accelerate its immunology pipeline targeting key immune‑related diseases. The round highlights strong investor interest in biotech innovations.
Endpoints News
Deals•Feb 6, 2026
Agomab Therapeutics and SpyGlass Pharma Set to IPO on Friday
Fibrosis‑focused Agomab Therapeutics and eye‑disease company SpyGlass Pharma announced they will go public on Friday, marking a significant week for biotech IPOs. The offerings are expected to boost the biotech sector's comeback after a slowdown.
Endpoints News
Deals•Feb 5, 2026
Generate:Biomedicines Files for IPO to Commercialize AI-Driven Drugs
Generate:Biomedicines, a Flagship Pioneering-backed AI bio startup, has filed for an initial public offering just nine days after dosing its first patient in a Phase 3 trial. The filing signals the company’s move to raise capital and bring AI-driven drug...
Endpoints News
Deals•Feb 5, 2026
Eikon Therapeutics Announces IPO Amid Valuation Cut
Bay Area biotech startup Eikon Therapeutics is preparing for an initial public offering, shifting from its $1 billion fundraising history. The analysis highlights a significant valuation cut as the company moves toward going public, marking a major event in the biotech...
Endpoints News
Deals•Feb 5, 2026
Veradermics Surges 122% on Debut as Biotech Goes Public
Biotech firm Veradermics, developing an oral form of Rogaine, completed its initial public offering, with its shares jumping 122% on the first day of trading. The strong debut reflects investor enthusiasm for the growing aesthetics market and the company's innovative...
Endpoints News
Deals•Feb 5, 2026
Angitia Biopharma Secures $130M Series D to Advance Musculoskeletal Drug Pipeline
US-China biotech Angitia Biopharmaceuticals announced a $130 million Series D financing to support three biologics in clinical testing for musculoskeletal diseases. The funding will advance its pipeline, including a candidate that previously fell short at Ultragenyx, highlighting investor confidence in...
Endpoints News
Deals•Feb 3, 2026
Menlo Ventures and A16z Back AI Startup Phylo in Undisclosed Funding Round
Menlo Ventures and Andreessen Horowitz (a16z) have invested in Phylo, an AI scientist startup founded by Stanford researchers Le Cong, Yuanhao Qu, Kexin Huang, and Jure Leskovec. The funding round was announced on February 3, 2026, with undisclosed terms.
Endpoints News
Deals•Jan 29, 2026
Agomab Therapeutics Targets $182M Nasdaq IPO to Fund Fibrosis Pipeline
Belgian biotech Agomab Therapeutics announced plans for a Nasdaq IPO to raise approximately $182 million in net proceeds. The capital will support the development of its fibrosis drug pipeline, with the company aiming to sell 12.5 million shares. The offering...
Endpoints News
Deals•Jan 29, 2026
Premise Health to Merge with Crossover Health to Expand Employer Clinics
Premise Health, an advanced primary care provider, announced a merger with Crossover Health, which runs on‑site health clinics for large employers such as Google and Amazon. The combined company aims to broaden its employer clinic network and help control rising...
Endpoints News
Deals•Jan 28, 2026
Veradermics Targets $181.8M Net Proceeds in Upcoming IPO
Biotech firm Veradermics, developing an oral version of Rogaine, announced plans to go public and raise approximately $181.8 million in net proceeds. The proposed IPO will fund late‑stage testing and commercialization of its hair‑loss treatment.
Endpoints News
Deals•Jan 28, 2026
Cellares Secures $257M Series D Funding to Accelerate Global Expansion and Target 2027 IPO
Clinical-stage cell therapy manufacturer Cellares announced a $257 million Series D funding round to support its global expansion and commercial rollout. The capital will also fund preparations for a planned initial public offering in 2027, highlighting investor confidence in its...
Endpoints News
Deals•Jan 27, 2026
Boehringer Ingelheim to Acquire IBD Bispecific From Simcere for €42M
German pharma Boehringer Ingelheim has agreed to pay €42 million upfront to Shanghai-based Simcere Pharmaceutical for an IBD bispecific drug candidate, marking a new partnership in immunology.
Endpoints News
Deals•Jan 27, 2026
TRexBio Raises $50M in Series B Extension for Treg Clinical Development
Bay Area biotech TRexBio announced an additional $50 million to its 2024 Series B round, aimed at advancing its pipeline of regulatory T cell (Treg) candidates into clinical trials. The funding will support further development and expansion of its immunotherapy...
Endpoints News
Deals•Jan 27, 2026
Insilico Medicine Secures $120M Drug Discovery Pact with Qilu Pharma
Insilico Medicine announced a $120 million partnership with Chinese pharmaceutical firm Qilu Pharma to develop cardiometabolic therapies. The collaboration will leverage Insilico's AI-driven drug discovery platform to accelerate the identification of novel candidates. The deal highlights growing interest in AI-powered...
Endpoints News
Deals•Jan 27, 2026
Wisp Acquires Sexual Health Startup TBD Health
Virtual women's health platform Wisp announced the acquisition of sexual healthcare startup TBD Health, expanding its tele‑health services. The deal, reported on Jan. 27, 2026, aims to broaden Wisp's offerings in women's sexual health.
Endpoints News
News•Jan 22, 2026
Drugmakers Spent Less on Washington Lobbying in 2025's Final Quarter
The five largest biotech firms reduced their congressional lobbying expenditures in the fourth quarter of 2025, marking a modest decline from the previous quarter. Collectively, they spent roughly $45 million, down about 4 percent year‑over‑year. The dip reflects tighter corporate budgets and...
By Endpoints News
News•Jan 22, 2026
Corcept's Drug Extends Patients' Lives in Key Ovarian Cancer Study
Corcept Therapeutics announced that its experimental drug, when combined with standard chemotherapy, cut the risk of death by 35% for patients with a difficult-to‑treat form of ovarian cancer. The reduction was observed in a Phase 2 trial that met its primary...
By Endpoints News
News•Jan 22, 2026
Roche Boosts NC Factory Investment to $2B; Rentschler CEO Steps Down
Roche’s Genentech is increasing its capital outlay for the Holly Springs, North Carolina manufacturing complex to nearly $2 billion, marking a substantial boost to its U.S. production capacity. The additional funds will expand biologics and vaccine output, positioning the site as a...
By Endpoints News
News•Jan 22, 2026
Bristol Myers Signs Deal with Janux on T Cell Engager for $50M Upfront
Bristol Myers Squibb has entered a collaboration with San‑diego biotech Janux Therapeutics to develop a novel tumor‑activated T‑cell engager for solid cancers. The agreement provides Janux with a $50 million upfront cash payment, along with potential milestone and royalty payments. Janux...
By Endpoints News
News•Jan 22, 2026
Erasca, Corvus, BioAge Target $500M+ Offerings
Erasca announced the pricing of an upsized public offering of common stock that pushes its capital raise beyond $500 million. Around the same time, Corvus Therapeutics and BioAge Labs filed registration statements for similarly sized equity offerings, signaling a coordinated surge...
By Endpoints News
News•Jan 22, 2026
#JPM26: Hua Medicine Plots Diabetes Drug Expansion in China and Beyond
Shanghai‑based Hua Medicine announced a strategic push to broaden its diabetes drug portfolio, aiming to capture a larger slice of the global market. The company is developing an oral GLP‑1 alternative that promises lower dosing and cost advantages over existing...
By Endpoints News
News•Jan 22, 2026
BioMarin Vets Spearhead New Biotech with $82M for Rare Disease Drugs
Former BioMarin executives have launched a new biotech focused on rare‑disease therapeutics, securing $82 million in seed financing. The capital will be used to acquire orphan‑drug candidates that lack commercial partners and to advance them through pre‑clinical and early‑clinical stages. The...
By Endpoints News
Deals•Jan 22, 2026
BioMarin Veterans Launch New Biotech, Raise $82M for Rare Disease Drug Development
Former BioMarin executives have founded a new biotech focused on rare disease therapeutics. The startup announced an $82 million fundraising round to support development of orphan drugs. The capital will be used to acquire and advance promising rare disease candidates.
Endpoints News
Deals•Jan 22, 2026
Erasca Announces Upsized Public Offering of Common Stock
Erasca announced the pricing of an upsized public offering of its common stock, aiming to raise over $500 million. The offering, part of a broader $500M+ target for several biotech firms, was disclosed in a press release on Jan. 22,...
Endpoints News
News•Jan 21, 2026
The Status of EU Drug Price Talks Depends on Who You Ask
European drug price negotiations for 2026 are at a crossroads, with member states and the EU Commission offering conflicting perspectives. U.S. policymakers are lobbying for tighter price alignment to curb American market spillover, while European regulators stress sovereign health budgets....
By Endpoints News
News•Jan 21, 2026
J&J Praises New FDA Guidance to Speed Development of Multiple Myeloma Drugs
The FDA released a draft guidance aimed at accelerating the development of multiple myeloma therapies by clarifying the use of surrogate endpoints and adaptive trial designs. Johnson & Johnson, which already markets several approved MM drugs, welcomed the guidance as...
By Endpoints News
News•Jan 21, 2026
Johnson & Johnson Brushes Off MFN Impact, Sees Strong Growth for 2026
Johnson & Johnson downplayed the impact of the new Most‑Favored‑Nation (MFN) pricing clause on its earnings, asserting that existing contracts and a diversified portfolio cushion any downside. The company projected a robust growth trajectory through 2026, driven by its oncology...
By Endpoints News
News•Jan 21, 2026
Tanabe Pill Delays Blood Disorder; enGene Adds up to $100M From Loans
Tanabe Pharma announced that its oral melanocortin‑1 receptor (MC1R) agonist achieved its primary endpoint in a Phase 2 trial for a rare blood disorder, delivering a 60% response rate among patients. The pill offers a non‑injectable option that could reduce transfusion...
By Endpoints News
News•Jan 21, 2026
IntraBio Says Rare Disease Drug Passes Phase 3, Will Seek FDA Approval
IntraBio announced that its experimental therapy for ataxia‑telangiectasia (A‑T) achieved statistically significant improvement in motor function in a pivotal Phase 3 trial. The study met its primary endpoint and demonstrated a favorable safety profile across a genetically defined patient cohort....
By Endpoints News
News•Jan 21, 2026
#JPM26: Regeneron, Lilly, Summit on Rivals Crowding Into Same Targets
Drug makers Regeneron, Eli Lilly and Summit Therapeutics are converging on identical biological targets, intensifying competition for potential megablockbuster therapies. The firms are pursuing treatments for diseases lacking effective options, hoping to capture large market share. Their pipelines reveal overlapping...
By Endpoints News
News•Jan 21, 2026
Exclusive: Claim Health Raises $4.4M to Help Home Care Providers Get Paid
Claim Health announced a $4.4 million financing round aimed at expanding its AI‑driven platform that manages the entire revenue‑cycle for home‑care providers. The startup moves beyond earlier AI tools that only handled isolated administrative tasks, now offering end‑to‑end claim submission,...
By Endpoints News
News•Jan 21, 2026
Think Bioscience Gets $55M to Unearth New Drug Pockets
Think Bioscience, a Boulder‑based biotech, announced a $55 million Series A round that was oversubscribed by investors. The capital will fund its platform that seeks previously hidden binding pockets on proteins and other molecules. By targeting these cryptic sites, the company aims...
By Endpoints News
Deals•Jan 21, 2026
Claim Health Secures $4.4M Funding to Streamline Home Care Payments
Claim Health, a health‑tech startup, announced a $4.4 million fundraising round to develop AI‑driven solutions that automate payment processes for home‑care providers. The capital will support product development and scaling, with investors not disclosed at the time of the announcement.
Endpoints News
News•Jan 20, 2026
Government Funding Bill Features PBM Reforms, Voucher Reauthorization
The U.S. House will vote on a bipartisan continuing resolution to keep the federal government operating beyond Jan. 30, bundling sweeping pharmacy‑benefit‑manager (PBM) reforms and a reauthorization of the children's health voucher program. The PBM provisions aim to increase pricing transparency,...
By Endpoints News
News•Jan 20, 2026
EU Parliament Adopts Stricter Drug Stockpiling Rules Under Critical Medicines Act
The European Parliament approved amendments to the Critical Medicines Act, introducing stricter drug‑stockpiling requirements and new financial incentives for manufacturers. The legislation mandates a minimum safety‑stock level—roughly 5 % of a product’s annual EU consumption—and tighter reporting on supply‑chain data. Companies...
By Endpoints News
News•Jan 20, 2026
Valneva Withdraws Chikungunya Vaccine From US
Valneva announced the withdrawal of its chikungunya vaccine from the United States, removing the product from the market and suspending a post‑marketing study. The decision follows internal safety assessments and regulatory feedback. The company has not provided detailed efficacy data,...
By Endpoints News
News•Jan 20, 2026
Clinician Groups Ask Court to Overturn CDC's Childhood Vaccine Overhaul
Leading physician organizations have filed a federal lawsuit seeking to overturn the CDC’s recent overhaul of the U.S. childhood vaccine schedule. The groups contend the new recommendations are reckless and lack adequate safety evidence. The legal challenge targets the addition...
By Endpoints News
News•Jan 20, 2026
Teladoc’s Mental Health Arm BetterHelp Has Quietly Expanded the Use of AI
BetterHelp, Teladoc's flagship mental‑health platform, has quietly broadened its use of artificial intelligence across multiple service layers. The AI tools now support client intake, symptom triage, and therapist recommendation workflows, aiming to streamline care delivery. BetterHelp claims the expansion will...
By Endpoints News
News•Jan 20, 2026
Pfizer to Depart GSK's ViiV as Shionogi Doubles Its Stake
Pfizer announced it will withdraw from ViiV Healthcare, the HIV specialist joint venture it formed with GSK over a decade ago. Shionogi will step into Pfizer's slot, doubling its ownership stake in ViiV. The move reshapes the ownership balance of...
By Endpoints News
News•Jan 20, 2026
Corvus' New Phase 1 Atopic Dermatitis Data Meet High Expectations
Corvus Pharmaceuticals announced that its Phase 1 trial for a novel severe atopic dermatitis therapy met predefined safety and efficacy benchmarks. The data demonstrated favorable tolerability and early signs of clinical improvement, prompting the company to advance the program into...
By Endpoints News
News•Jan 20, 2026
J&J, Isomorphic Sign Research Deal for AI-Made Molecules
Isomorphic Labs, a Google DeepMind spin‑out specializing in AI‑driven drug design, announced its third pharmaceutical collaboration, signing a multi‑target research agreement with Johnson & Johnson. The partnership will leverage Isomorphic’s generative‑AI platform to design novel molecules across several therapeutic areas....
By Endpoints News
News•Jan 20, 2026
GSK Makes $2.2B Deal for RAPT and Its Food Allergy Candidate
GlaxoSmithKline announced a $2.2 billion acquisition of RAPT, a privately held biotech focused on food allergy therapies. The deal includes RAPT’s lead candidate, a novel oral immunotherapy for peanut and other food allergies, which has shown promising Phase 2 data. The transaction,...
By Endpoints News
News•Jan 20, 2026
Exciva Raises $59M Series B to Fund Phase 2 Test of Alzheimer’s Agitation Drug
Exciva announced a €51 million ($59 million) Series B round to finance the Phase 2 clinical trial of its lead candidate targeting agitation in Alzheimer’s disease. The funding, led by several biotech‑focused venture firms, will support enrollment, biomarker development, and regulatory preparation. The trial...
By Endpoints News
Deals•Jan 20, 2026
Shionogi Acquires Pfizer's Stake in ViiV, Doubling Its Ownership
Pfizer announced it will exit the HIV specialist joint venture ViiV, which it co‑founded with GSK. Shionogi will take over Pfizer’s share, doubling its stake in the company. The move reshapes ViiV’s ownership and strengthens Shionogi’s position in the HIV...
Endpoints News
Deals•Jan 20, 2026
GSK to Acquire RAPT for $2.2B
GlaxoSmithKline (GSK) announced a $2.2 billion acquisition of biotech firm RAPT, securing its food allergy candidate. The deal was unveiled at the JP Morgan Healthcare Conference, marking a major M&A move in the pharma sector.
Endpoints News
Deals•Jan 20, 2026
Exciva Secures $59M Series B Funding to Advance Alzheimer’s Agitation Drug
Exciva announced a €51 million ($59 million) Series B financing round to fund Phase 2 testing of its candidate drug targeting agitation in Alzheimer’s disease. The capital will support clinical development and expand the company's pipeline.
Endpoints News
News•Jan 17, 2026
JPM Recap; Mirador Raises $250M; Genentech’s PBM Shift; and More
The JPMorgan Healthcare Conference (JPM26) highlighted a surge in biotech financing, with several firms announcing sizable funding rounds. Mirador Therapeutics disclosed a $250 million Series B raise to accelerate its gene‑therapy platform. Genentech revealed plans to bring its pharmacy‑benefit‑manager (PBM) operations in‑house,...
By Endpoints News
News•Jan 16, 2026
Agomab and SpyGlass File for IPOs as Investor Enthusiasm Builds After JPM
SpyGlass Pharma and Agomab Therapeutics announced filings for initial public offerings on Friday, signaling a new wave of biotech listings. Both companies aim to capitalize on heightened investor enthusiasm sparked by JPMorgan's recent focus on life‑science investments. SpyGlass plans to...
By Endpoints News
News•Jan 16, 2026
AbbVie, Genmab Say Epkinly Didn't Prolong Overall Survival in Lymphoma Study
AbbVie and Genmab announced that their antibody‑drug conjugate Epkinly failed to extend overall survival in a Phase 3 trial for diffuse large B‑cell lymphoma (DLBCL). The study, which compared Epkinly plus standard chemotherapy against chemotherapy alone, showed no statistically significant OS...
By Endpoints News
News•Jan 16, 2026
Drugmakers without MFN Pacts Are Bracing to Make One
Last year President Donald Trump urged almost all U.S. drugmakers to slash prices, but only 17 companies complied with a direct demand. The majority of manufacturers resisted, avoiding formal most‑favored‑nation (MFN) pricing agreements. Industry analysts now warn that, facing renewed...
By Endpoints News
News•Jan 16, 2026
Makary Talks FDA's Plans to Combat China's Biotech Growth
FDA Commissioner Marty Makary announced that the agency is overhauling its Phase 1 clinical‑trial framework to address the rapid influx of Chinese biotech firms into the U.S. market. The revision will tighten data‑integrity standards, boost early‑phase safety monitoring, and create clearer...
By Endpoints News
News•Jan 16, 2026
ImmunityBio's Cell Therapy Posts Encouraging Early Data in Rare Blood Cancer
ImmunityBio reported encouraging early data from its off‑the‑shelf cell‑therapy platform in a Phase 1 trial (QUILT) targeting a rare form of lymphoma. The small study demonstrated a favorable safety profile and preliminary efficacy signals, including objective responses in several patients. The...
By Endpoints News
News•Jan 16, 2026
#JPM26: Sandoz CEO on Ozempic Generic Launch Plans for 2026
Sandoz, Novartis' generics arm, announced plans to launch a generic version of Ozempic (semaglutide) in 2026. The move aligns with the anticipated expiration of Novo Nordisk's patents on the GLP‑1 drug, opening the U.S. and European markets to lower‑priced alternatives....
By Endpoints News
News•Jan 16, 2026
European Regulators Recommended 38 Novel Drugs in 2025, 15 Fewer than the FDA
The European Medicines Agency (EMA) recommended 104 medicines for approval in 2025, marking the second‑highest total in the past 15 years. Of those, 38 are classified as novel drugs, a figure that trails the U.S. Food and Drug Administration (FDA)...
By Endpoints News
News•Jan 16, 2026
Novo Nordisk, BioMarin Make AI Moves; Bristol Myers Welcomes Neurology Exec From Eisai
Novo Nordisk and BioMarin announced strategic partnerships to integrate artificial intelligence into their drug discovery pipelines, aiming to accelerate candidate identification and reduce development costs. Novo Nordisk highlighted a collaboration with a leading AI firm to model peptide therapeutics, while...
By Endpoints News
News•Jan 15, 2026
New York Sues Ex-Emergent CEO over Insider Trading During Vaccine Manufacturing Struggle
New York Attorney General sued the former chief executive of Emergent BioSolutions, alleging he engaged in insider trading while the company grappled with contamination problems at its Baltimore plant that delayed AstraZeneca’s COVID‑19 vaccine production. Prosecutors claim the executive sold...
By Endpoints News
News•Jan 15, 2026
Inside Fosun Pharma's Ambition to Reach Outside of China
Shanghai‑based Fosun Pharmaceutical is accelerating its transformation from a domestic generic manufacturer into a global innovator. The group has earmarked billions of dollars for overseas R&D hubs, strategic biotech partnerships and a new $2.5 billion bond to fund its expansion. Recent...
By Endpoints News
News•Jan 15, 2026
Alfasigma Gains Neuro Treatment; BridgeBio Offers $550M in Notes
Alfasigma has secured worldwide rights to a parenteral formulation of adibelivir for the treatment of HSV encephalitis, an ultra‑rare neurological condition. The agreement positions Alfasigma to commercialize the therapy across major markets. Meanwhile, BridgeBio announced a $550 million senior unsecured note...
By Endpoints News
News•Jan 15, 2026
FDA to Meet Novo Nordisk on Troubled Site; AbbVie Buys Drug-Device Factory
The U.S. Food and Drug Administration will meet with Novo Nordisk early this year to review remediation progress at its Indiana manufacturing site, which has been under heightened scrutiny after contamination and production setbacks. The meeting follows a series of...
By Endpoints News
News•Jan 15, 2026
Ocugen Touts Phase 2 Data for Eye Disease Gene Therapy
Ocugen announced positive interim Phase 2 data for its geographic atrophy (GA) gene therapy, a leading cause of vision loss in age‑related macular degeneration. The trial, though limited to a small patient cohort, demonstrated measurable improvements in retinal function and...
By Endpoints News
News•Jan 15, 2026
J&J Reports Positive Phase 3 Data for Tecvayli in Earlier Blood Cancer Setting
Johnson & Johnson announced that its bispecific antibody Tecvayli (teclistamab) achieved a statistically significant overall survival benefit in a Phase 3 trial evaluating an earlier‑line setting for multiple myeloma. The study reported a hazard ratio of 0.68 for death and extended...
By Endpoints News
News•Jan 15, 2026
Novo Nordisk Foundation to Inject $850M+ Into BioInnovation Institute Through 2035
The Novo Nordisk Foundation announced a commitment of 5.5 billion Danish kroner (approximately $857 million) to the BioInnovation Institute, a life‑science and deep‑tech incubator, with funding extending through 2035. The pledge aims to bolster the institute’s capacity to nurture early‑stage biotech and...
By Endpoints News
Deals•Jan 15, 2026
AbbVie Acquires Drug-Device Factory
Pharmaceutical giant AbbVie announced the acquisition of a drug-device manufacturing facility, expanding its presence in the medical device sector. The deal was reported on January 15, 2026, with financial terms undisclosed.
Endpoints News
News•Jan 14, 2026
Scribe Therapeutics Plans to Test Cholesterol-Lowering Therapy This Summer
The request does not contain the full text of the article titled “Scribe Therapeutics plans to test cholesterol‑lowering therapy this summer,” only a brief placeholder and a sign‑up prompt. Without the substantive content, no executive summary can be generated.
By Endpoints News
News•Jan 14, 2026
Manufacturers Benefit as Pharma Customers Invest Back in US
Recent tariff and trade policy shifts that unsettled pharmaceutical firms in 2025 are now creating upside for U.S. manufacturers. Pharma companies are redirecting capital toward domestic production, spurring demand for contract manufacturing and equipment. This investment wave is expected to...
By Endpoints News
News•Jan 14, 2026
Jazz Sells Priority Review Voucher for $200M, Scoring Highest Price in a Decade
Jazz Pharmaceuticals announced the sale of a priority review voucher to an undisclosed buyer for $200 million, marking the highest price paid for such a voucher in a decade. The voucher, originally granted for developing a treatment for a neglected disease,...
By Endpoints News
News•Jan 14, 2026
Health Tech Funding Rounds Get Bigger when Andreessen Horowitz and General Catalyst Join
Rock Health’s latest report shows a handful of venture firms dominate health‑tech financing. When Andreessen Horowitz and General Catalyst join a round, the deal size expands dramatically, with average rounds climbing from roughly $30 million to $50 million. Together these two firms...
By Endpoints News
News•Jan 14, 2026
ImmunityBio's Anktiva Lung Cancer Data; Glaukos' Glaucoma Implant Sales Disappoint
ImmunityBio announced that its lymphocyte‑stimulating agent Anktiva, combined with checkpoint inhibitors, restored immune cells and produced objective responses in a non‑small‑cell lung cancer (NSCLC) study. The data suggest the combination could enhance the efficacy of existing immunotherapies. Meanwhile, Glaukos reported...
By Endpoints News
News•Jan 14, 2026
Thermo Fisher to Lay Off 421 Workers as It Winds Down Lab Product Site in North Carolina
Thermo Fisher Scientific announced it will phase out operations at its laboratory products facility in Asheville, North Carolina, laying off 421 workers. The shutdown is slated to be completed by the end of 2026, ending the site’s production of consumables...
By Endpoints News
News•Jan 14, 2026
#JPM26: Day 3 at the JP Morgan Healthcare Conference
Day three of the JPMorgan Healthcare Conference saw sessions winding down as investors turned their attention to key presentations, notably from Chinese contract research giant WuXi AppTec. The company used its slot to unveil a refreshed drug‑development platform and hint...
By Endpoints News
News•Jan 14, 2026
#JPM26: Q&A with Bristol Myers Squibb CEO Chris Boerner on 2026 Outlook
Chris Boerner, in his third year as Bristol Myers Squibb CEO, opened the JPMorgan Healthcare Conference with a forward‑looking Q&A on the company’s 2026 outlook. He outlined a $45 billion revenue target, driven by late‑stage oncology and immunology assets, while emphasizing...
By Endpoints News
News•Jan 13, 2026
FDA Delays Decision on Expanding Label for Travere's Kidney Disorder Drug
The FDA has extended its review of Travere Therapeutics’ kidney‑disorder drug by three months, pushing the expected decision past today’s deadline. The agency’s delay pertains to a pending label expansion for a rare renal condition, which could broaden the drug’s...
By Endpoints News
Deals•Jan 12, 2026
Eli Lilly and Nvidia Sign Five‑year, up to $1 Billion AI Laboratory Deal
Eli Lilly and Nvidia have entered a five‑year partnership valued at up to $1 billion to create an AI laboratory aimed at accelerating drug discovery. The collaboration builds on a prior agreement to build pharma’s largest supercomputer and will leverage Nvidia’s...
Endpoints News
Deals•Jan 9, 2026
Aktis Oncology Lands Biotech's First IPO of 2026, Raising $318M
Aktis Oncology, a radiopharmaceutical startup partnered with Eli Lilly, announced its initial public offering on the Nasdaq, raising $318 million. The IPO marks the first biotech offering of 2026, positioning the company for growth in the radiopharma sector.
Endpoints News
Deals•Jan 9, 2026
Medipost Raises $140M to Expand Korean Stem Cell Therapy to US and Japan
South Korean biotech Medipost announced a $140 million fundraising round to commercialize its allogeneic cell therapy, approved in South Korea since 2012, in the United States and Japan. The capital will support regulatory approvals and market entry in these regions.
Endpoints News
Deals•Jan 8, 2026
Beacon Therapeutics Raises $75M Series C Led by Goldman Sachs Alternatives
Beacon Therapeutics announced a $75 million Series C financing round to advance its vision treatment pipeline. The round was led by Goldman Sachs Alternatives, with participation from a managing partner of the firm’s life sciences team. The funding aims to...
Endpoints News
Deals•Jan 8, 2026
Vizgen Raises $48M in Series E Round to Expand Spatial Biology and Multiomics Tools
Vizgen, a startup developing spatial biology and multiomics mapping technologies, announced a $48 million Series E funding round. The capital will be used to accelerate product development and market expansion. The round underscores continued investor interest in biotech innovation.
Endpoints News
Deals•Jan 8, 2026
French Biotech Enodia Therapeutics Raises €20.7M with Pfizer Backing
Enodia Therapeutics, a French biotech founded in February, announced it has raised €20.7 million (approximately $24 million) to develop protein degrader technology. The financing was aided by pharmaceutical giant Pfizer, marking a significant early-stage corporate investment in the company.
Endpoints News
Deals•Jan 8, 2026
Boltz Secures $28M Seed Funding to Build Open AI Models in Biology
Biotech startup Boltz announced a $28 million seed round to develop open AI models for biology. The funding will support the creation of large language models that predict biomolecular structures, building on advances like AlphaFold. The round highlights growing investor...
Endpoints News
Deals•Jan 8, 2026
Servier Launches €200M Corporate Venture Capital Unit for European Biotech Startups
French pharmaceutical group Servier announced the creation of a corporate venture capital unit focused on European biotech startups, initially funded with about €200 million ($232.9 million). The new VC arm aims to back emerging biotech innovations, joining a wave of large pharma...
Endpoints News
Deals•Jan 8, 2026
Parabilis Medicines Raises $305M to Tackle Undruggable Proteins
Parabilis Medicines announced a $305 million financing round to develop therapies targeting undruggable proteins. The capital will fuel its platform to address challenging protein targets, highlighting strong investor interest in biotech solutions for hard‑to‑drug diseases.
Endpoints News
Deals•Jan 8, 2026
Alveus Therapeutics Raises $159.8M in Series A to Expand Obesity Drug Pipeline
Alveus Therapeutics announced a $159.8 million Series A funding round on Thursday, aiming to accelerate its obesity drug development and challenge market leaders like tirzepatide and semaglutide. The capital will support the company's push into the space dominated by MariTide....
Endpoints News